4.5.6. pharmacological management. 4.5.6.1. alpha-adrenergic blockers alpha-adrenergic blockers postulated relieve luts caused boo women via smooth muscle relaxation bladder neck, thus decreasing bladder outlet resistance . systematic reviews use alpha-blockers women generally involve studies population includes women complaining luts voiding dysfunction. confirmation boo often required trials included . reviews showed significant improvements symptoms urodynamic parameters associated use [543-545]. meta-analysis fourteen rcts comparing alpha-blockers placebo women luts showed significant symptom relief alpha-blocker treatment relative placebo, significant difference qmax, pvr volume adverse event rates . contrast prospective non-comparative trials consistently showed improvements voiding storage symptoms, bother scores, urodynamic parameters (qmax, pvr, pdetqmax, mucp alpha-blocker use compared baseline) [492,493,546-548]. sr performed panel studies alpha-blockers used specifically women boo included one placebo-controlled rct, one rct comparing two types alpha-blockers, six prospective non-comparative studies . placebo-controlled rct reporting subgroup analyses women urodynamically proven boo (based blaivas-groutz nomogram) significant difference observed changes ipss, ipss sub scores, qmax, pvr volume bladder diary eight weeks alfuzosin (n = 58) vs. placebo (n = 59). note, emg and/or voiding cysto-urethrography used distinguish dysfunctional voiding primary bladder neck obstruction . information comparative effectiveness different types alpha-blockers limited one rct. small trial 37 women ipss > 8, qmax < 12 ml/s pvr volume > 50 ml, compared tamsulosin prazosin three-month treatment period. patients treated tamsulosin completely satisfied treatment (16/20 vs. 9/20). treatment groups showed significant improvement symptom scores baseline statistical comparison groups done. however, larger decrease aua symptom score seen tamsulosin group compared prazosin group. adverse events reported prazosin (thirteen vs. one case) . 4.5.6.2. striated muscle relaxants baclofen gamma-aminobutyric acid (gaba) agonist exerts effect gabaergic interneurons sacral inter-mediolateral cell column responsible relaxation striated urinary sphincter voiding. randomised placebo-controlled crossover trial investigated efficacy safety four-week course oral baclofen 10 mg three times/day 60 women diagnosed boo, based increased emg activity sustained detrusor contraction voiding. showed lower number voids, significant improvements qmax pdetqmax baclofen compared placebo. pvr volume, maximum cystometric capacity mucp significantly different groups. adverse event rates also similar, common somnolence, dizziness, nausea. important limitation study lack patient-reported outcomes assess symptoms qol . 4.5.6.3. oestrogens relative reduction urethral wall compliance seen atrophic urethritis due oestrogen deprivation may responsible urethral obstruction postmenopausal women. oestrogen therapy thus theoretically expected improve condition. published studies use oestrogens specifically management female boo. 4.5.6.4. sildenafil sildenafil, inhibiting phosphodiesterase five, increases levels nitric oxide female urethral sphincter, thereby promoting urethral relaxation. placebo-controlled, randomised crossover trial included twenty women partial complete retention obstructive voiding, high mucp elevated us-estimated sphincter volume (> 1.6 cm) showed significant improvement symptom scores urodynamic parameters baseline sildenafil treatment, difference significant compared placebo . 4.5.6.5. thyrotropin-releasing hormone intravenous thyrotropin-releasing hormone (trh) postulated neurotransmitter induces urethral relaxation . exact mechanism unclear. small rct sixteen women voiding difficulty, eight (three boo) randomised receive 200 Î¼g intravenous bolus trh, eight (three boo) received saline. difference decline functional profile lengths maximum urethral closure pressures noted treatment groups, despite significant decline noted baseline treatment group. subgroup analysis women boo reported . 4.5.6.6. summary evidence recommendations pharmacological management summary evidencelealpha-adrenergic blockers may associated improvement symptom scores baseline, urodynamic parameters compared placebo.1atamsulosin associated greater improvement symptom score compared prazosin.1boral baclofen better placebo improving qmax pdetqmax, urodynamic parameters. effects symptoms well reported.1bcurrent evidence show sildenafil superior placebo improving symptoms urodynamic parameters female patients boo.1btrials including women voiding problems mixed aetiologies showed difference urodynamic outcomes intravenous trh placebo.1b recommendationsstrength ratingoffer uroselective alpha-blockers, off-label option, women functional bladder outlet obstruction (boo) following discussion potential benefits adverse events.weakoffer oral baclofen women boo, particularly increased electromyography activity sustained detrusor contraction voiding.weakonly offer sildenafil women boo part well-regulated clinical trial.strongdo offer thyrotropin-releasing hormone women boo.strong